Mark Shearman, MD, PhD

Dr. Shearman joined AGTC as Chief Scientific Officer in 2015. He was employed most recently by EMD Serono, Inc., the US and Canadian subsidiary of Merck KGaA, where he served as Senior Vice-President of Research & Early Development since 2009. Previously, Dr. Shearman was Executive Director of Merck & Co. Research Laboratories, Boston, and Senior Director at the Merck Sharp & Dohme Research Laboratories Neuroscience Research Centre, UK. Dr. Shearman earned a BSc from the University of Bristol, a PhD from the University of Nottingham and conducted academic research at institutes in Japan and Germany.